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Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed
vaccines or speciﬁc antiviral drugs against this infection are not available. To identify novel anti-DENV
compounds, we screened 1280 pharmacologically active compounds using focus reduction assay.
Bromocriptine (BRC) was found to have potent anti-DENV activity and low cytotoxicity (half maximal
effective concentration [EC50], 0.8e1.6 mM; and half maximal cytotoxicity concentration [CC50], 53.6 mM).
Time-of-drug-addition and time-of-drug-elimination assays suggested that BRC inhibits translation and/
or replication steps in the DENV life cycle. A subgenomic replicon system was used to verify that BRC
restricts RNA replication step. Furthermore, a single amino acid substitution (N374H) was detected in the
NS3 protein that conferred resistance to BRC. In summary, BRC was found to be a novel DENV inhibitor
and a potential candidate for the treatment of DENV infectious disease.
© 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Dengue virus (DENV) is transmitted to humans by Aedes
mosquitoes; it causes dengue fever (DF) and dengue hemorrhagic
fever (DHF), which is a self-limiting febrile illness (Gubler,1998). DF
is relatively mild, but DHF leads to the life-threatening dengue
shock syndrome (DSS); mortality in patients diagnosed with DHF
and DSS is 1e5%. DENV annually infects 50e100 million humans in
tropical and sub-tropical regions, posing a considerable publicer; DHF, dengue hemorrhagic
ral; BRC, bromocriptine; HTS,
ion; hpi, hours post infection.
Project, Tokyo Metropolitan
tagaya-ku, Tokyo, 156-8506,
iki).
er B.V. This is an open access artichealth problem in over 100 countries (Simmons et al., 2012; WHO,
2013).
DENV belongs to the family Flaviviridae and consists of four
serotypes (DENV1e4). These viruses are enveloped and have a
single-stranded positive-sense RNA genome of approximately 11 kb
(Lindenbach et al., 2007). A single long open reading frame of the
viral RNA encodes a polyprotein that is processed by cellular and
viral proteases into three structural (C, prM, and E) and seven non-
structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5). The structural proteins form the virus particles and play roles
in receptor binding, virus fusion, and virion assembly. NS proteins
are responsible for the replication of the viral genome and evasion
from host immunity.
Many antiviral compounds have been reported to inhibit DENV
replication in vitro and in vivo (Lim et al., 2013). High-throughput
screening (HTS) using viral-enzyme assay, and subgenomicle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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by screening chemical libraries (Lim et al., 2013; Noble et al., 2010;
Wang et al., 2015; Yang et al., 2014; Zou et al., 2011b). However, no
approved antiviral drug is yet available for the treatment of DENV
infectious disease.
In this study, we screened small-molecule chemical library,
LOPAC®1280, for agents with antiviral activity against infectious
DENV-1 by using focus reduction assay and found that 2-bromo-a-
ergocriptine (bromocriptine: BRC) could inhibit DENV replication.
BRC interfered with DENV post-translation and/or RNA synthesis
steps. Furthermore, a single amino acid substitution in the NS3
protein (N374H) was involved in resistance to BRC. These ﬁndings
suggest that BRC inhibits DENV replication by targeting the NS3
protein.
2. Materials and methods
2.1. Cell culture
Baby hamster kidney cells (BHK-21) and African green monkey
kidney cells (Vero) were maintained in Eagle’s minimum essential
medium (EMEM; Life Technologies, USA) supplemented with 10%
fetal bovine serum (FBS; JR Scientiﬁc), penicillin, and streptomycin
sulfate (Nacalai Tesque, Japan) under 5% CO2 at 37 C. Human
hepatoma Huh7 cells and human embryonic kidney (293T) cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium (Life
Technologies, USA) supplemented with 10% FBS and antibiotics
under 5% CO2 at 37 C. Hybridoma-producing anti-E antibody (HB-
112) was maintained in Roswell Park Memorial Institute 1640
medium (RPMI1640; Life Technologies, USA) supplemented with
10% FBS and antibiotics under 5% CO2 at 37 C, and its supernatant
was centrifuged at 1000  g for 5 min.
2.2. Viruses
DENV-1 02-20 strain was derived from a full-length infectious
cDNA clone, D1 (02-20)/pMW119 (Tajima et al., 2006). DENV-2
16681 strain was kindly provided by Dr. Takeshi Kurosu and Dr.
Kazuyoshi Ikuta (Research Institute for Microbial Diseases, Osaka
University, Japan). DENV-3 00-40 (Ito et al., 2007) and DENV-4 09-
48 strains (unpublished) were isolated in 2000 from a Japanese
traveler returning from Thailand and in 2009 from a Japanese
traveler returning from Indonesia, respectively. These DENV1-4
strains were cultured in Vero cells. TBEV Oshima strain was prop-
agated in BHK-21 cells (Takashima et al., 1997). These viruses were
stored at 80 C until use.
2.3. Focus reduction assay and chemical compounds
BHK-21 cells were seeded in a 96-well plate (5  104 cells per
well). At 1 day after seeding, DENV-1 (02-20 strain) was infected at
50 focus forming units per well. After 1 h of incubation, culture
supernatant was replaced with EMEM containing 2% FBS,1%methyl
cellulose, and 10 mM of the test compound. After additional 3 days
of cultivation, cells were ﬁxed with 4% paraformaldehyde and
permeabilized with 0.01% Triton X-100. The permeabilized cells
were incubated with 4G2, which was produced from HB112 hy-
bridoma, as the primary antibody. Next, Dako Envision kit/HRP was
used as the secondary antibody, and di-amino benzidine tetra hy-
droxyl carbonate was used for staining.
The LOPAC®1280 library (SigmaeAldrich, USA) was used for
screening in this study. Additional bromocriptine (BRC; bromo-
criptine mesylate) and other dopamine agonists quinpirole and
rotigotine were purchased from SigmaeAldrich.2.4. MTT assay
BHK-21 cells were seeded in a 96-well plate (5  104 cells per
well). After 3 days of cultivation with the compound (0e10 mM),
30 mL of 0.5% 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) solution was added to each well. After 3 h of in-
cubation, the supernatant was replaced with 100 mL of methanol
with 1% Triton-X100, and then vortexed vigorously to dissolve the
formazan. Absorbance at 565 nm and reference at 655 nm were
measured using a microplate reader (Berthold Technologies, Ger-
many). Half maximal cytotoxicity concentration (CC50) was calcu-
lated using the Reed and Muench method (Reed and Muench,
1938).
2.5. Plaque assay
BHK-21 cells were seeded in 12-well plates (5  105 cells per
well). After 1 h of DENV inoculation, EMEM supplemented with 2%
FBS and 1% methyl cellulose was added, and the cells were incu-
bated for additional 5e6 days. Next, the cells were ﬁxed with 3.7%
formaldehyde in phosphate buffered saline (PBS) and stained with
methylene blue. The half maximal effective concentration (EC50)
against each virus was calculated as described above.
2.6. Time-of-drug-addition assay
BHK-21 cells were seeded in 12-well plates (5  105 cells per
well). The cells were infected with DENV-1 (multiple of infection
[MOI] ¼ 1) for 1 h. Next, the viral inoculum was removed, and the
cells were washed twice with PBS. At 0, 2, 4, 6, 8, 12, 18, and 24 h
post-infection, 10 mM of BRC was added to the infected cells. After
24 h of infection, cell culture supernatant was collected, and viral
titer was measured using the plaque assay.
2.7. Time-of-drug-elimination assay
BHK-21 cells were seeded in 12-well plates (5  105 cells per
well). The cells were infected with DENV-1 at MOI of 1 for 1 h. Next,
the cells were washed with PBS twice, and fresh medium con-
taining 10 mM BRC was added. After 2, 4, and 6 h of infection, the
cells were washed with PBS twice and were cultivated in fresh
medium. After 24 h of infection, cell culture supernatant was
collected, and viral titer was measured by plaque assay.
2.8. Transient DNA-based subgenomic replicon assay
A transient replicon assay was conducted using DNA-based
Gaussia luciferase expressed replicon (DGL2) and DGL2-mut as
described previously (Kato et al., 2014). BHK-21 cells were seeded
in 24-well plates (2.5  105 cells per well) and transfected with
100 ng of DGL2 or DGL2-mut by using X-treamGENE HP DNA
transfection reagent (Roche Diagnostics, Schweiz), and 0e10 mM of
each compound was added at time zero. The cell culture medium
was collected and replaced with fresh medium containing 10 mM of
each compound every 24 h. The luciferase activity of the culture
medium was measured using a microplate reader.
2.9. Production and isolation of mutant DENV-1 resistant to BRC
BHK-21 cells (5  105) were seeded in 6-well plates and
infected with DENV-1 at MOI of 0.01 for 1 h. After infection, cul-
ture medium was replaced with fresh medium containing 10 mM
BRC. At 3 or 4 days after transfection, the cell culture supernatant
was collected and inoculated to naive BHK-21 cells containing
10 mM BRC for 16 times. The supernatant was subjected to plaque
F. Kato et al. / Antiviral Research 131 (2016) 141e147 143puriﬁcation, and the viruses representing each plaque were
propagated in BHK-21 cells in the presence of BRC. Plaque puriﬁ-
cation was performed as follows: BHK-21 cells were inoculated
with bulk virus in EMEM containing 2% FBS, 10 mM BRC, and 1%
low-melting agarose (Roche Diagnostics, Switzerland). After 5
days of cultivation, EMEM containing Neutral Red was added, and
the observed plaque was picked up and transferred to naive BHK-
21 cells. The isolated 12 independent viruses were propagated in
BHK-21 cells. The bulk virus (after 16 consecutive passages) and 12
plaque-derived isolates were assessed for their sensitivity against
10 mM BRC.
2.10. Reverse transcription polymerase chain reaction and
sequencing
The viral RNA was extracted and puriﬁed using a viral RNA
extraction kit (Qiagen, Germany) following the manufacturer’s in-
structions. cDNA was synthesized using SuperScript-III (Life Tech-
nologies, USA) and ampliﬁed using KOD-Plus Neo (TOYOBO, Japan)
as 5 fragments. The ampliﬁed DNA was puriﬁed using NucleoSpin
Gel and PCR Clean-up (Macherey-Nagel, Germany), sequenced us-
ing Big-Dye Terminator v3.1, and analyzed on an ABI3130xl Genetic
Analyzer (Applied Biosystems, USA).
2.11. Construction of N374H mutant virus and subgenomic replicon
clone
A point mutation at the 374th amino acid of NS3 protein from
asparagine (N) to histidine (H) was inserted into the infectious
molecular clone DENV1 (02-20)/pMW119, designated N374H virus,
and reporter subgenomic replicon DGL2, designated N374H repli-
con. Brieﬂy, high-ﬁdelity inverse PCR was performed using 50-
phosphorylated primers. The PCR product was ligated and trans-
formed to Stbl2 competent cells (Life Technologies, USA). Se-
quences of mutant plasmids were veriﬁed as above described.
These plasmids were transfected to 293T cells using Lipofectamine
2000 (Life Technologies, USA) and cultured for 3 days. The virus
titer of cell culture supernatant was measured using plaque assay.
2.12. Statistical analysis
Data are expressed as means and standard deviations (SD). All
statistical analyses were performed using Student’s t-test; P < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Identiﬁcation of compounds with anti-DENV activity from the
chemical libraries
Novel anti-DENV compounds were identiﬁed by conducting
focus reduction assay by using small molecule library consisting of
1280 pharmacologically active compounds. In the primary
screening, BHK-21 cells infected with DENV-1 (02-20 strain) were
cultured in the presence of each compound at a ﬁnal concentration
of 10 mM and reduction of viral focus formation was assessed. Next,
compounds causing cell toxicity were excluded by evaluating
cytotoxicity by using the MTT assay as the secondary screening
(Fig. 1A). Through these screenings, 2-bromo-a-ergocriptine
(bromocriptine: BRC) was identiﬁed as one of potent inhibitors of
DENV-1, with an EC50 of 1.6 mM and a CC50 of 53.6 mM (Fig. 1B, C and
Table 1). Among the hit compounds, we also found naltrindole,
which has been reported as a potent DENV inhibitor that targets the
NS4B protein (van Cleef et al., 2013). The inhibiting effect of BRC
against the other DENV serotypes and other ﬂaviviruses was alsoexamined. The antiviral activity of BRC against DENV-2 to DENV-4
and tick-borne encephalitis virus (TBEV) was analyzed using plaque
assay. BRC showed antiviral activity against not only DENV-1 but
also other DENV serotypes and TBEV. The EC50 against DENV-2, 3, 4,
and TBEV were 1.2, 0.8, 0.8, and 11.3 mM, respectively (Fig. S1 and
Table 1). Since dengue fever is a human disease, we further inves-
tigated the anti-DENV-1 property of BRC in human A549, Huh7, and
293T cells and conﬁrmed its antiviral activity in these cells without
cytotoxicity (Fig. S2). Because BRC has been reported to be an
agonist of dopamine receptors 2 and 3 (Geurts et al., 1999;
Perachon et al., 1999; Velasco and Luchsinger, 1998), whether the
agonistic activity was associated with the antiviral effect was then
examined. Unexpectedly, quinpirole (mainly D2 receptor agonist
(Fernandez-Duenas et al., 2012)) and rotigotine (mainly D3 recep-
tor agonist (Scheller et al., 2009)) did not suppress DENV-1 repli-
cation (Fig. 1D). These results suggest that BRC inhibits ﬂavivirus
genus replication through a mechanism that is independent of the
already-known pharmacological action.
3.2. BRC inhibits early stage of DENV life cycle
The stage of DENV life cycle that is affected by BRC was deter-
mined by performing time-of-drug-addition assay. During a single
ﬂaviviral life cycle, viral proteins are translated from genomic RNA
in the ﬁrst 1e5 h post infection (hpi); viral RNA synthesis occurs
after 5 hpi, and progeny virions are assembled and released after
12 hpi (Chambers et al., 1990; Qing et al., 2009; Wang et al., 2011)
(Fig. 2A). At 0, 2, 4, 6, 8, 12, and 18 hpi, culture medium was
changed to 10 mM BRC-containing medium. At 24 hpi, the viral titer
in the culture supernatant was quantiﬁed using plaque assay. The
addition of BRC up to 6 hpi signiﬁcantly reduced the virus yield
(Fig. 2B). This result suggests that BRC might inhibit an early stage
in the DENV life cycle. The target of BRC to DENV replication stage
was also deﬁned by performing time-of-drug-elimination assay.
The data showed that BRC did not suppress the virus titer in the
culture supernatant up to 2 hpi, although the virus titer was
signiﬁcantly suppressed when treatment commenced at 4 hpi
(Fig. 2C). Thus, we concluded that viral attachment and
entry stages were unlikely to be the points of action targeted by
BRC.
3.3. BRC suppresses DENV RNA replication
To further clarify the mechanism of BRC-mediated DENV sup-
pression, we used a reporter subgenomic replicon assay. The
transient replicon system is a useful tool for estimating the stage of
action (Fig. 3A). BRC remarkably reduced the level of luciferase
activity 72 h post transfection with DGL2 in a dose-dependent
manner (Fig. 3B); however, it did not affect the luciferase activity
of non-replicative mutant DGL2-mut at any concentration tested
(Fig. 3C). These results suggest that BRC inhibits DENV replication in
the stages between post translation and viral RNA genome
replication.
3.4. Isolation of BRC-resistant cloned virus
The responsible region in viral elements was identiﬁed by
generating BRC-resistant virus variants by conducting 16 serial
passages of DENV in the presence of 10 mM BRC. Resistance of these
virus variants against 10 mM BRC was conﬁrmed by conducting
plaque reduction assay (data not shown). Next, BRC-resistant
cloned viruses were isolated by plaque puriﬁcation, and we ob-
tained 12 clones. Among these clones, 4 were equally resistant to
10 mM BRC, as revealed by plaque assay. Viral RNA from the 4
resistant clones was puriﬁed and reverse transcribed to generate
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Fig. 1. BRC inhibits DENV replication. (A) Flow chart of the screen. (B) Structural formula of BRC. (C) BRC inhibits DENV replication in a dose-dependent manner. (D) Quinpirole and
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Table 1
EC50 of BRC against DENV1-4 and TBEV.
EC50 (mM) CC50 (mM)
DENV-1 DENV-2 DENV-3 DENV-4 TBEV
1.6 1.2 0.8 0.8 11.3 53.6
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susceptibility to BRC was mapped by determining the nucleotide
sequences of the cloned viruses and comparing them to the parent
DENV-1 (02-20). Although several mutations were found in the
viral genome, the only commonmutation among 4 viral clones was
asparagine (N) to histidine (H) at the 374th amino acid in NS3
(N374H) (Table 2).3.5. Efﬁcacy of mutation in NS3 for conferring BRC resistance
Next, we examined whether N374H mutation is the responsible
region for BRC resistance by inserting the mutation into the mo-
lecular clone of the parent strain and reporter replicon, DGL2. The
mutant virus and replicon were cultured in the presence of
increasing amount of BRC ranging from 0 to 10 mM, and the viral
titer or luciferase activity was measured in the cell culture super-
natant. The sensitivity curve of N374H mutant was shifted to a
higher concentration of BRC compared with that in the parent vi-
rus, although the plaque size was smaller and the growth kinetics
was lower than the parent virus. The EC50 of parent virus was
1.6 mM, whereas that of the N374H virus was slightly higher, 3.1 mM
(Fig. 4A). In the replicon system, susceptibility to BRC showed
similar trend. The EC50 of the parent replicon was 1.6 mM, and that
of the mutant replicon was similarly as high (2.5 mM) as that of the
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F. Kato et al. / Antiviral Research 131 (2016) 141e147 145mutant virus (Fig. 4B). Although the N374H mutation does not
confer complete resistance to BRC, it does produce a reduced sus-
ceptibility to BRC.4. Discussion
DENV is the most common human arthropod-borne virus and
causes a severe problem worldwide, mainly in tropical and sub-tropical regions. However, a licensed vaccines and speciﬁc chemi-
cal treatments against DENV infectious diseases are not available;
hence, the development of antiviral compounds has been desired.
We screened a chemical library by using viral focus reduction assay
to identify novel anti-DENV compounds. Focus assay is a relatively
low-throughput method but enables the evaluation of all the steps
of viral life cycle. Therefore, we used DENV-102-20 strain and BHK-
21 cells to perform HTS for clear focus formation and easy access to
positive/negative signals in 96-well plates. Through the screening,
we identiﬁed a novel DENV inhibitor, BRC, in a small compound
Table 2
Mutation sites in BRC resistant DENV genome.
Associated protein (Amino acid position) NS2B (87) NS3 (191) NS3 (305) NS3 (374) NS3 (617) NS4B (79) NS4A (83) NS5 (5) NS5 (316)
WT K I V N G G P Q A
clone1 T I A H A W A E A
clone2 K R A H A W P Q A
clone3 K I A H G G P Q A
clone4 K I V H G G P Q T
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Fig. 4. Efﬁcacy of mutation in NS3 for conferring BRC resistance. (A) Viral titer at 72
hpi in the culture supernatant of BHK-21 cells infected with wild-type DENV1 (WT) or
N374H mutant (N374H) treated with 0e10 mM of BRC. (B) Luciferase activity in BHK-
21 cells transfected with DGL2 (WT) or DGL2-N374H mutant (N374H) treated with
0e10 mM of BRC at 72 h post-transfection. All data were normalized to their control
(0 mM of BRC). Each data point represents the average (±standard deviation) from
triplicate experiments.
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BRC has been reported to be an agonist of dopamine receptors 2
and 3, and it is approved as a remedy for galactorrhea and Par-
kinson’s disease (Ginther et al., 2012; Perachon et al., 1999; Zhang
et al., 1999). In this study, the other dopamine receptor agonists,
quinpirole and rotigotine, did not show anti-DENV activity,
although BRC showed antiviral activity against all DENV serotypes
1e4 and TBEV. The inhibitory effect of BRC on TBEV replication was
lower than its effect on DENV (Table 1). We assume that the viral
replication rate is related to the efﬁcacy of BRC. In fact, the propa-
gation rate of TBEV was higher than that of DENV1e4. This ﬁnding
could be explained by the two viruses differing in their level of
dependence on the factor that BRC targets for their replication.
These results suggest that BRC might inhibit the replication of a
spectrum of Flaviviridae species, with varying efﬁcacy.
Many antiviral compounds were selected as inhibitors of viral
enzymes. During ﬂavivirus drug development, some compounds
targeted viral enzyme activities such as protease, helicase, MTase,and RdRp. We examined the inﬂuence of BRC on DENV NS2B3
protease, but no effect on viral protease activity was observed
(Fig. S3). Furthermore, we assessed the effect of BRC on protease,
NTPase, and RdRp activities using AlphaScreen assay (Takahashi
et al., 2012), but no effect on viral enzyme activities was observed
(data not shown). Thus, other viral proteins or host factors are likely
to be involved in the antiviral mechanism exerted by BRC.
Time-of-drug-addition and time-of-drug-elimination assays
suggested that BRC inhibited the translation or RNA synthesis steps
in DENV life cycle. Furthermore, replicon assay showed that BRC
restricts the same step of virus life cycle. Our subgenomic replicon
system could speciﬁcally analyze translation and viral genome RNA
replication steps, because DGL2 replicon deleted a large part of the
genomic region containing structural genes in DENV. Consequently,
the replicon system is a useful tool for not only screening the anti-
viral reagentsbut alsoevaluating the speciﬁc steps invirus life cycles.
The analysis of resistant mutants to BRC revealed that a single
mutation (N374H) in NS3 protein could confer partial resistance to
BRC. NS3 and NS5 are essential components of the replication
complex consisting of several viral non-structural proteins as well
as host proteins. Physical interaction of NS3 helicase domain region
which includes N374 has been reported for NS4B and NS5 (Chen
et al., 1997; Kapoor et al., 1995; Tay et al., 2015; Umareddy et al.,
2006; Zou et al., 2011a, 2015) as well as several host proteins
(Aguirre et al., 2012; Heaton et al., 2010; Khadka et al., 2011; Luo
et al., 2015). These results suggested that the 374th amino acid is
one of multiple regions targeted by BRC and other mutations or
combinations might be required for complete resistance. We also
note that N374H is a conservative change and BRC may still be able
to bind to the target albeit less efﬁciently. We propose that BRC will
serve as a useful tool compound to understand the details of the
ﬂaviviral RNA replication mechanismwhich can lead to new target
identiﬁcation and the design and development of speciﬁc
antivirals.
Animal models are preclinical tools to evaluate the in vivo efﬁ-
cacy of antiviral compounds or vaccines (Chan et al., 2015; Omatsu
et al., 2011). We also preliminary evaluated the in vivo efﬁcacy of
BRC using the AG129 mouse (deﬁcient in interferon alpha/beta and
gamma receptors) model (Watanabe et al., 2012), however, the
compound was not beneﬁcial to viremia reduction or mouse sur-
vival (Fig. S4). In vivometabolism might inﬂuence its efﬁcacy. Thus,
further improvement of the compound and careful in vivo obser-
vation may be required if our ﬁnding is translated into clinical
settings.
Taken together, BRC has novel antiviral activity against ﬂavivi-
rus, especially DENV, and it restricts the post-translation or early
RNA synthesis steps. BRC is an approved agent for treatment of
other diseases and can be used as an anti-DENV drug. However, the
detailed mechanisms of its antiviral activity need to be identiﬁed
for it to be developed as an anti-DENV drug. Such investigations
should employ an appropriate model, such as cultured primary
human cells. Moreover, in vivo studies using non-human primate
models may be also beneﬁcial to understanding the pharmacoki-
netics and antiviral activity of BRC for its application as a novel
antiviral drug (Omatsu et al., 2011).
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Glossary
2-Bromo-a-ergocriptine bromocriptine
Half maximal cytotoxicity concentration CC50
Half maximal effective concentration EC50
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